What's new? Log in Free sign up

Filing search / Olema Pharmaceuticals, Inc. / "Nature"

Search information

Olema Pharmaceuticals, Inc.

Companies

"Nature"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

67 results

Newest first Best match first

OLMA Olema Pharmaceuticals, Inc.

Quarterly report

consolidated financial statements. Table of Contents Olema Pharmaceuticals, Inc. Notes to condensed consolidated financial statements (Unaudited) 1.Nature … adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial statements

6 Aug 24

4:15pm

OLMA Olema Pharmaceuticals, Inc.

Entry into a Material Definitive Agreement

that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the availability

OLMA Olema Pharmaceuticals, Inc.

Quarterly report

to condensed consolidated financial statements (Unaudited) 1.Nature of the Business and Basis of Presentation Olema Pharmaceuticals, Inc. (“Olema … of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated

8 May 24

4:15pm

OLMA Olema Pharmaceuticals, Inc.

Definitive proxy

has examined each Audit Committee member’s scope of experience and the nature of her or his employment in the corporate finance sector. The primary … of Conduct, we will disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K. Information contained in, or that can

26 Apr 24

5:07pm

OLMA Olema Pharmaceuticals, Inc.

in target lesions and evidence of activity in both ESR1 wild-type and ESR1-mutant patients. Given the advanced and heavily pretreated nature … . Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States

11 Mar 24

4:15pm

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Quarterly report

7 Nov 23

4:12pm

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

$130.00 mm in equity, sold $130.00 mm, 12 investors

Olema Oncology Announces Combined Financing for Up to $180 Million

cqj 2829xwgj04slgzz

Olema Oncology Announces Combined Financing for Up to $180 Million

f9ca8ph5rkcm66s9n

Olema Oncology Announces Combined Financing for Up to $180 Million

Quarterly report

8 Aug 23

4:12pm

Quarterly report

9 May 23

4:08pm

Quarterly report

9 May 23

4:08pm

Quarterly report

9 May 23

4:08pm

kkhxm2c30tqvfn6v

Quarterly report

9 May 23

4:08pm

Definitive proxy

28 Apr 23

4:05pm

Prev
1
2
3
4
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.